FANCI-FANCD2 stabilizes the RAD51-DNA complex by binding RAD51 and protects the 5′-DNA end by Sato, Koichi et al.
Title FANCI-FANCD2 stabilizes the RAD51-DNA complex bybinding RAD51 and protects the 5′-DNA end
Author(s)
Sato, Koichi; Shimomuki, Mayo; Katsuki, Yoko; Takahashi,
Daisuke; Kobayashi, Wataru; Ishiai, Masamichi; Miyoshi,
Hiroyuki; Takata, Minoru; Kurumizaka, Hitoshi




© The Author(s) 2016. Published by Oxford University Press
on behalf of Nucleic Acids Research.; This is an Open Access
article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-
nc/4.0/), which permits non-commercial re-use, distribution,





10758–10771 Nucleic Acids Research, 2016, Vol. 44, No. 22 Published online 30 September 2016
doi: 10.1093/nar/gkw876
FANCI-FANCD2 stabilizes the RAD51-DNA complex by
binding RAD51 and protects the 5′-DNA end
Koichi Sato1, Mayo Shimomuki1, Yoko Katsuki2, Daisuke Takahashi1, Wataru Kobayashi1,
Masamichi Ishiai2, Hiroyuki Miyoshi3, Minoru Takata2 and Hitoshi Kurumizaka1,4,*
1Laboratory of Structural Biology, Graduate School of Advanced Science & Engineering, Waseda University, 2-2
Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan, 2Laboratory of DNA Damage Signaling, Department of Late
Effects Studies, Radiation Biology Center, Kyoto University, Kyoto 606-8501, Japan, 3Department of Physiology, Keio
University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan and 4Institute for
Medical-oriented Structural Biology, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
Received May 29, 2016; Revised August 22, 2016; Accepted September 21, 2016
ABSTRACT
The FANCI-FANCD2 (I-D) complex is considered to
work with RAD51 to protect the damaged DNA in the
stalled replication fork. However, the means by which
this DNA protection is accomplished have remained
elusive. In the present study, we found that the I-D
complex directly binds to RAD51, and stabilizes the
RAD51-DNA filament. Unexpectedly, the DNA bind-
ing activity of FANCI, but not FANCD2, is explicitly
required for the I-D complex-mediated RAD51-DNA
filament stabilization. The RAD51 filament stabilized
by the I-D complex actually protects the DNA end
from nucleolytic degradation by an FA-associated
nuclease, FAN1. This DNA end protection is not ob-
served with the RAD51 mutant from FANCR patient
cells. These results clearly answer the currently enig-
matic question of how RAD51 functions with the I-D
complex to prevent genomic instability at the stalled
replication fork.
INTRODUCTION
DNA interstrand crosslinks (ICLs), arising from endoge-
nous aldehydes or anti-cancer crosslinking agents, stall
replication fork progression (1–3). Fanconi anemia (FA)
is an infantile hereditary disorder with severe manifesta-
tions, such as bone marrow failure, predisposition to can-
cers and cellular hypersensitivity to ICL-inducing agents
(4–6). Nineteen FA-causal genes have been identified from
the FA patient cells (7). Among the FA proteins, FANCI
and FANCD2 form the I-D complex, which is monoubiqui-
tinated by the FA core complex, composed of FANCA, -B, -
C, -E, -F, -G, -L, -M, FAAP20, FAAP24, FAAP100,MHF1
and MHF2 (8–11). FANCL is a ubiquitin E3 ligase sub-
unit, and interacts with a ubiquitin E2 conjugating enzyme,
UBE2T (FANCT) (12–16). The I-D complex preferentially
binds to branched DNA structures, such as the stalled
replication fork (17), and its DNA binding drastically en-
hances the FANCL-UBE2T complex-mediated FANCD2
monoubiquitination (18–20). The monoubiquitinated I-D
complex is considered to function in recruiting structure-
specific nucleases to the damaged DNA site, and to remove
the affected bases at the ICL site (21–27).
RAD51 is a eukaryotic recombinase that functions in
meiotic homologous recombination andmitotic DNA dou-
ble strand break (DSB) repair (28,29). During DSB repair,
RAD51 promotes homologous pairing between the single-
stranded DNA (ssDNA) produced at the DSB site and the
homologous double-stranded DNA (dsDNA) (30–32). Re-
cently, a heterozygous RAD51 mutation (RAD51 T131P),
in which Thr131 is replaced by Pro, was identified as an
FANCR gene in an infant with FA (33). Another missense
RAD51 mutation (RAD51 R150Q), in which Arg150 is re-
placed by Gln, was also reported in bilateral breast cancer
patients (34,35). These facts demonstrate that RAD51 plays
an important role in the suppression of tumorigenesis.
Emerging evidence has indicated that RAD51 accumu-
lates on ICL-induced stalled replication forks, and protects
the stalled replication fork from undesired degradation by
exonucleases recruited by the I-D complex (33,36). In fact,
defects in RAD51 assembly at the stalled replication fork
resulted in excessive nucleolytic degradation of the nascent
DNA strand by the exonucleases, including the MRE11,
DNA2 and FAN1 nucleases, leading to chromosomal in-
stability (33,37–41). Interestingly, the I-D complex report-
edly colocalizes with RAD51 at the nascent DNA region
of stalled replication forks, and plays a role in the RAD51-
mediated nascent DNA protection (42–45). However, the
mechanism by which the I-D complex and RAD51 cooper-
atively protect genomic DNA in the stalled replication fork
has remained elusive.
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In the present study, we found that the I-D complex di-
rectly binds to RAD51, stabilizes the RAD51-DNA fila-
ment and protects the DNA end from nucleolytic degra-
dation by an FA-associated nuclease, FAN1. This work
explains how RAD51 and the I-D complex cooperatively
function to prevent genomic instability at the stalled repli-




The DNA fragment encoding chicken RAD51 was ampli-
fied by polymerase chain reaction from the DT40 cDNA
library, using the following primers: 5′-GGAAT TCCAT
ATGGC CATGC AGGTG CAGTT CGAGG C-3′ and
5′-TCCCG CGGAT CCTTA TTCTT TTGCA TCTCC
CACTC CATCA G-3′. The amplified DNA fragment was
ligated into the NdeI-BamHI sites of the pET15b vector
(Novagen). The FANCRmutation, in which Thr131 was re-
placed by Pro, was introduced in the chickenRAD51 cDNA
by using a KOD mutagenesis kit (TOYOBO) with the fol-
lowing primers: 5′-CGGGA AAAAC ACAGT TGTGC
CATAC TTTGG-3′ and 5′-GACGA AACTC CCCAA
ATAAT TCTGT TATGG AC-3′. The RAD51 F86E mu-
tation, in which Phe86 was replaced by Glu, was intro-
duced into the chicken RAD51 cDNA by using a KOD
mutagenesis kit (TOYOBO) with the following primers: 5′-
GAAAC CACAG CAACG GAATT CCATC-3′ and 5′-
ACCCA TCGGA ACCAG TTTAG CTG-3′.
For the generation of the expression vector for the
chicken FAN1 nuclease domain (amino acids 385–1034 of
chicken FAN1), the DNA fragment encoding full-length
chicken FAN1 was ligated into the NdeI-BamHI sites of
the pET15b vector. The cDNA of the FAN1 nuclease do-
main was amplified by using a KOD mutagenesis kit with
the following primers: 5′-CCATA TTACC TCCGA AA
CTT TTTAA TGGTG TTG-3′ and 5′-GCTGC CGCGC
GGCAC CAGGC CGCTG CTG-3′. For the FAN1 nucle-
ase domain mutant, in which Asp977 was replaced by Ala,
the amino acid substitution was introduced in the FAN1
cDNA by using a KOD mutagenesis kit with the following
primers: 5′-CGCTG GTTGT GTGGA GTACT CACAG
CAATCAC-3′ and 5′-CAGGAAGCCCCCCTCTGCAA
TGGCG CAGAT CTTTG-3′.
The DNA fragment encoding the chicken
FANCD2(Ex7) mutant, in which Lys361, Lys369, Arg399,
Lys400, Lys404, Arg407 and Lys974 were replaced by Glu,
was generated by the site directed mutagenesis method
using a KOD mutagenesis kit with the following primer
pairs: 5′-AGCTT GGATT GAAGC TATTG AGAAC
AGCAC ATCTG-3′/5′-TCAGA GACAT CTTCC
TGGAA TCTTA CAGCT TGC-3′, 5′-GAGGA AGTAT
TGGAA AGCAA GATTC GCCTG GGC-3′/5′-AGTTT
GTTCT TCGTT CTTGC TGTTC GTAGA ATGG-3′
and 5′-GAACT GGAAC ATGTG CTGAC CCCAG
GCTCC AC-3′/5′-CCAGC ACATG TCATC CAGAA
GGAAG CAGAG-3′.
Generation of cell line
The construction of the human U2OS cells expressing
C-terminally 3xFLAG-tagged FANCD2 will be described
elsewhere. In brief, a 3xFLAG-tag sequence was knocked-in
at the termination codon of the endogenous FANCD2 gene
locus, using TALEN technology. To produce doxycycline-
inducible GFP-RAD51 expressing U2OS cells, the cDNA
encoding the N-terminally GFP-tagged RAD51 was in-
serted into the entry vector pENTR (Invitrogen). The re-
sulting vector was transferred into a puromycin-resistant
derivative of CSIV-TRE-RfA-UbC-KT (46), using LR
Clonase (Invitrogen). U2OS cells were infected with the
lentivirus, and were selected in the presence of puromycin
(0.5 g/ml).
Cell culture
U2OS cells were maintained in Dulbecco’s Modified Ea-
gle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). HeLa cells and hTERT-immortalized
fibroblasts (1BR3.hTERT) were maintained in DMEM
(Low Glucose) supplemented with 10% FBS. FANCD2-
deficient fibroblasts stably expressing GFP, GFP-FANCD2
or GFP-FANCD2 K561R, in which the ubiquitination
target Lys561 was replaced by Arg, were maintained in
-MEM supplemented with 1 g/ml puromycin (Sigma-
Aldrich) and 15% FBS, as previously described (47). DT40
cells weremaintained inRPMI-1640medium supplemented
with 10% fetal calf serum, 1% chicken serum, 2 mM L-
glutamine, 50 M 2-mercaptoethanol, penicillin and strep-
tomycin.
RNA interference and immunoblotting
The FANCD2-specific siRNA (5′-CAGAG UUUGC UU
CAC UCUCU AdTdT-3′) and the control siRNA (5′-
UCGAA GUAUU CCGCG UACGdT dT-3′) were in-
troduced into immortalized human fibroblasts or U2OS
cells using LipofectamineRNAiMAX (Invitrogen), accord-
ing to the manufacturer’s protocol. Whole cellular pro-
teins were prepared 3 days after the siRNA transfection,
fractionated by 6 or 10% SDS-PAGE, and immunoblot-
ted with a mouse monoclonal antibody directed against -
tubulin (1:5000; B-5-1-2, Sigma-Aldrich), or a rabbit poly-
clonal antibody against either FANCD2 (1:5000; NB100-
182, Novus) or RAD51 (1:5000; 48). Secondary antibody
treatment was performed with a sheep anti-mouse IgG,
HPR-linked species-specific F(ab’)2 fragment (1:10 000
for -tubulin; GE Healthcare) or a donkey anti-rabbit
IgG, horseradish peroxidase (HRP)-linked species-specific
F(ab’)2 fragment (GEHealthcare; 1:10 000 for RAD51 and
FANCD2). Signals were detected by the ECL Prime West-
ern Blotting Detection Reagent (GE Healthcare).
Immunofluorescence
Immortalized fibroblasts, PD20F cells or U2OS cells were
grown on coverslips (Matsunami, 0.17 mm thickness), and
were transfected with siRNA, followed by fixation and per-
meabilization with 0.5% Triton X-100, 3% paraformalde-
hyde and 2% sucrose in phosphate buffered saline (PBS),
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for 30 min on ice at 0–25 h after 100 ng/ml mitomycin C
(MMC) treatment or at 5 h after 4 mM hydroxyurea (HU)
treatment (2–3 days post transfection). For RAD51 stain-
ing, the permeabilized cells were treated with rabbit anti-
RAD51 (1:2000) and Alexa Fluor 594 goat anti-rabbit IgG
(1:500, Molecular Probes). The fluorescence images were
obtained using the BZ II viewer application connected to
a BZ-9000 fluorescence microscope (KEYENCE) with a
Plan Apo  40X/NA 0.95 objective lens (Nikon). All cap-
tured images were analyzed by the BZ II analyzer software
(KEYENCE). To assess the RAD51 foci, the fluorescent in-
tensities of RAD51 in >100 cells were analyzed, and were
normalized by each gross area of the nucleus. Statistical dif-
ferences were determined by Bonferroni’s multiple compar-
ison test with the Prism software (GraphPad Software Inc.).
In situ proximity ligation assay (PLA)
PLA experiments were performed according to the manu-
facturer’s protocol, using a DuoLink Kit (Sigma-Aldrich).
For the PLA experiments between RAD51 and FLAG-
tagged FANCD2, cells were treated with 100 ng/ml MMC
or 0.5 mMHU (or not treated) for 24 h, and were fixed with
2% sucrose, 3% bovine serum albumin (BSA) and 0.5% Tri-
ton X-100 in PBS, followed by staining with an anti-FLAG
tag (anti-DDDDK-tag) mouse Ab (1:500; PM020, MBL)
and an anti-RAD51 rabbit Ab (1:500). For the PLA ex-
periments between RAD51 and PCNA, cells were trans-
fected with the control siRNAor the FANCD2 siRNA, and
were fixed at 48 h after transfection. The HU treatment (4
mM) was performed for 2.5 h immediately before sample
fixation. The cells were then stained with an anti-PCNA
mouse Ab (1:500; PC10, Santa Cruz Biotechnology, Inc.)
and an anti-RAD51 rabbit Ab (1:500). PLA signals were
detected with a fluorescencemicroscope (BZ-9000), and nu-
clear PLA signals were analyzed by counting the red sig-
nals onDAPI-stained blue areas, using the hybrid cell count
software (KEYENCE). In total, >50 cells were analyzed,
andwere plotted in each column. Statistical differenceswere
determined by the Student’s t-test with the Prism software.
Fluorescence recovery after photobleaching (FRAP)
U2OS cells producingGFP-RAD51 were grown inDMEM
supplemented with 10% FBS, on glass-bottom dishes, and
were transfected with either the control siRNA or the
FANCD2 siRNA. After cultivation for 24 h, the cells were
treated with doxycycline (1 ng/ml) to induce the GFP-
RAD51 production, and were further grown for 24 h in ei-
ther the presence or absence of MMC (100 ng/ml). FRAP
was then performed using a TCS SP5 II confocal micro-
scope (Leica), equipped with an INU incubator system for
microscopes (Tokai Hit), at 37◦C with a 5% CO2 atmo-
sphere. Two confocal images of a field containing a nucleus
were collected, using an HCX PL APO 63x/1.40–0.60 Oil
CS objective lens (512 × 512 pixels, zoom 8, scan speed 400
Hz and 2% transmission of 488-nm laser). One-quarter to
one-half of each nucleus was bleached using 100% trans-
mission at 488 nm (five iterations), and images were ac-
quired using the original settings at 3 s intervals. The fluo-
rescence intensities of the bleached GFP-RAD51 foci were
measured using Image J 1.46r (Rasband, http://rsb.info.nih.
gov/ij/). After background subtraction, the intensities of the
bleached foci were normalized to the initial intensity before
bleaching.
Preparation of recombinant proteins
Human RAD51 was overexpressed in E. coli JM109(DE3)
cells, which contain the minor tRNA expression vector
(Codon(+)RIL; Stratagene), at 30◦C, and was purified by
the method described previously (49). Chicken RAD51 was
purified by the samemethod as that for humanRAD51. For
the purification of the chicken RAD51 T131P mutant, the
spermidine precipitation step was omitted. These RAD51
proteins were produced as N-terminally His6-tagged pro-
teins, and the His6 tag was removed by thrombin pro-
tease treatment during the purification processes. For the
purification of the His6-tagged chicken RAD51 and the
His6-tagged chicken RAD51 F86E mutant, the thrombin
protease treatment and the spermidine precipitation steps
were omitted. The purified His6-tagged RAD51 was dia-
lyzed against 1 l of buffer A, containing 20 mM HEPES-
NaOH (pH 7.5), 10% glycerol, 250 mM KCl, 50 mM NaF,
0.25 mM EDTA and 5 mM 2-mercaptoethanol. The His6-
tagged chicken RAD51 F86E mutant was further purified
by chromatography on a Superdex 200 column (HiLoad
26/60 preparation grade; GEHealthcare) equilibrated with
buffer A. In the Ni-NTA agarose (Qiagen) chromatography
step for the purification of the His6-tagged chicken RAD51
F86E mutant, the resin was washed with buffer containing
10 mM imidazole, instead of the buffer containing 60 mM
imidazole used for the His6-tagged chicken RAD51 purifi-
cation (wild type).
The FAN1 nuclease domain was overexpressed in E. coli
BL21(DE3) cells containing the Codon(+)RIL vector, at
18◦C. The cells producing the His6-tagged FAN1 nuclease
domain were collected by centrifugation, and were resus-
pended in buffer B, containing 50 mM Tris-HCl (pH 8.0),
10% glycerol, 500 mM NaCl, 1 mM phenylmethylsulfonyl
fluoride, 12 mM imidazole and 5 mM 2-mercaptoethanol.
The cells were then disrupted by sonication, and the super-
natant was separated from the cell debris by centrifugation
at 27 700 × g for 30 min. The supernatant was mixed gen-
tly with 3 ml of Ni-NTA agarose resin at 4◦C for 1 h, by
the batch method. The Ni-NTA agarose resin was packed
into an Econo-column (Bio-Rad), and was washed with
150 ml buffer B. The FAN1 nuclease domain was eluted
with a 60 ml linear-gradient of 12–400 mM imidazole in
buffer B. The peak fractions were pooled, and the sam-
ple was immediately dialyzed against 4 l buffer C, con-
taining 20 mM Tris-HCl (pH 8.0), 10% glycerol, 200 mM
NaCl and 5 mM 2-mercaptoethanol. The sample was then
loaded on a Q Sepharose Fast Flow column (2 ml; GE
Healthcare). The unbound fractions were pooled, and were
loaded on a Superdex 200 column (HiLoad 16/60 prepa-
ration grade; GE Healthcare) equilibrated with buffer C.
The purified FAN1 nuclease domain was concentrated, and
aliquots were frozen in liquid nitrogen. The FAN1 nuclease
domain (D977A) protein was prepared by the samemethod
as that for the wild-type FAN1 nuclease domain.
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Chicken FANCI, chicken FANCI(Ex6), chicken
FANCD2, human RPA and human DMC1 were pu-
rified as described previously (18,50,51). The I-D complex
was prepared by mixing FANCI and FANCD2 in a 1:1
stoichiometry. For the purification of FANCD2(Ex7), a Q
Sepharose Fast Flow column (3 ml) was employed, instead
of a Heparin Sepharose CL-6B column (GE Healthcare).
The column was washed with 150 ml buffer C containing
235 mM NaCl, and the proteins were eluted with a 60
ml linear gradient of 235–450 mM NaCl in buffer C. The
subsequent purification procedure for FANCD2(Ex7) was
the same as that for wild-type FANCD2. The protein
concentration was determined by the Bradford method
(52), using BSA as the standard protein.
DNA substrates
The 49-mer dsDNA was prepared by annealing oligonu-
cleotide 1, with the sequence 5′-GTCCC AGGCC ATTAC
AGATC AATCC TGAGC ATGTT TACCA AGCGC
ATTG-3′, and its complementary oligonucleotide, as de-
scribed previously (53). The 5′-biotinylated 3′-tailed DNA
was prepared by annealing the 5′-biotinylated oligonu-
cleotide 3 and the unmodified oligonucleotide 4, with the
sequences 5′-GTCCC AGGCC ATTAC AGATC AATCC
TGAGC ATGTT TACCA AGCGC ATTGT TTTTT
TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT
TTTTT TTTTT-3′ and 5′-CAATG CGCTT GGTAA
ACATG CTCAG GATTG ATCTG TAATG GCCTG
GGAC-3′, respectively. For the preparation of the 32P-
radiolabeled 3′-tailed DNA, oligonucleotide 4 labeled at
the 5′-end was annealed with the unmodified oligonu-
cleotide 3. The 5′-biotinylated replication fork-like DNA
was prepared by annealing the 5′-biotinylated oligonu-
cleotide 5 and the unmodified oligonucleotides 6, 7
and 8, with the sequences 5′-GTCCC AGGCC ATTAC
AGATC AATCC TGAGC ATGTT TACCA AGCGC
ATTGG CCTCG ATCCT ACCAA CCAGA TGACG
CGCTG CTACG TGCTA CCGGA AGTCG-3′, 5′-
CGACT TCCGG TAGCA CGTAG CAGCG CGTCA
TCTGG TTGGT AGGAT CGAGG C-3′, 5′-ATGGC
GCAGC GCATC CTGCA GCTGG CGGCC GTTTT
TTTTT TTTTT TTTTT TCAAT GCGCT TGGTA
AACAT GCTCA GGATT GATCT GTAAT GGCCT
GGGAC-3′ and 5′-CGGCC GCCAG CTGCA GGATG
CGCTG CGCCA T-3′, respectively. For the preparation of
the 32P-radiolabeled replication fork-like DNA, the 5′-end
(32P) labeled oligonucleotide 8 was annealed with the un-
modified oligonucleotides 5, 6 and 7. All of the oligonu-
cleotides were purchased from Nihon Gene Research Lab-
oratory, as HPLC-purified grade. DNA concentrations are
expressed in moles of nucleotides.
Pull-down assays
Purified human and chicken RAD51 were covalently con-
jugated with Affi-Gel 15 beads (Bio-Rad), according to the
manufacturer’s protocol. The control beads were prepared
by the same method, in the absence of RAD51. For the
cell-based pull-down assay, HeLa cell extracts were pre-
pared with lysis buffer, containing 20 mM Tris-HCl (pH
7.5), 150 mM NaCl, 0.5% NP-40, 1 mM phenylmethylsul-
fonyl fluoride, 2 mM NaF, 2 mM Na3VO4 and 1x protease
inhibitor cocktail (Nacalai Tesque), as previously described
(54). DT40 cell extracts were prepared by the same method
used for the HeLa cell extract preparation. The human and
chickenRAD51 beads (6.4g of protein) were gentlymixed
with the HeLa and DT40 cell extracts (1.5 mg of protein),
and were incubated in 20 mM Tris-HCl buffer (pH 7.5),
containing 100 mMNaCl, 6.6% glycerol, 0.017% Triton X-
100, 0.17% NP-40, 3.3 mM 2-mercaptoethanol, 0.67 mM
NaF, 0.67 mM Na3VO4 and 0.67x protease inhibitor cock-
tail, for 16 h at 4◦C. The cell lysates were treated with a nu-
clease, benzonase (50 unit/ml, Sigma-Aldrich), before the
addition of the RAD51 beads. Therefore, the RAD51 bind-
ing to the DNA-free FANCI-FANCD2 proteins was de-
tected. After the incubation, the beads were washed 3 times
with 1 ml of 20 mM Tris-HCl (pH 7.5) buffer, contain-
ing 75 mM NaCl, 10% glycerol, 0.025% Triton X-100 and
5 mM 2-mercaptoethanol. The endogenous FANCI and
FANCD2 that copelleted with the RAD51 beads were sepa-
rated by SDS-PAGE, and were detected by western blotting
with a human FANCD2-specific mouse monoclonal anti-
body (1:250; FI17, Santa Cruz Biotechnology, Inc.) or a
rabbit polyclonal antibody against either chicken FANCD2
(1:1000), humanFANCI (1:1000; A301-254A, Bethyl Labo-
ratories, Inc.) or chicken FANCI (1:1000). Human RAD51
and chickenRAD51were detected byWestern blotting with
a rabbit polyclonal antibody (1:1000).
For the pull-down assay with Ni-NTA beads, chicken
RAD51 (5.5 g) or human DMC1 (5.5 g) was incu-
bated with either His6-tagged FANCI (3.8 g), His6-tagged
FANCD2 (3.8 g) or His6-tagged FANCD2 complexed
with FANCI (7.6 g for the I-D complex) for 10 min at
37◦C in 100 l of pull-down buffer, containing 20 mM
Tris-HCl (pH 7.5), 10% glycerol, 150 mM NaCl, 0.025%
Triton X-100, 5 mM imidazole, 0.2 mM Ethylene diamine
tetraacetic acid (EDTA) and 2 mM 2-mercaptoethanol. Ni-
NTA agarose beads (4 l) were added to the reaction mix-
tures and were gently mixed for 50 min at 23◦C. The beads
were then washed three times with 1 ml pull-down buffer
containing 0.05% Triton X-100. For the pull-down assay
with His6-tagged RAD51 proteins, His6-tagged RAD51
(3.5 g) or His6-tagged RAD51 F86E (2 g) was gently
mixed with Ni-NTA agarose beads (3 l), for 45 min at
4◦C in 55 l of buffer A. At these protein concentrations,
the amounts of RAD51 and RAD51 F86E bound to the
Ni-NTA agarose beads were confirmed to be equal. After
washing with buffer A (300 l), the I-D complex (5.5 g)
was added to the beads and was gently mixed in 100 l of
the pull-down buffer containing 50 mM NaF, for 50 min
at 23◦C. The beads were then washed twice with the pull-
down buffer (1ml) containing 0.05%TritonX-100. The pro-
teins bound to the beads were separated by 5–20%, 10% or
12% SDS-PAGE and were visualized by Coomassie Bril-
liant Blue staining. The band intensities of the I-D complex,
RAD51 and DMC1 were quantitated with an LAS-4000
image analyzer (GEHealthcare), using theMultiGauge ver.
3.2 software (Fujifilm).
For the pull-down assay with magnetic streptavidin
beads, chicken RAD51 (3 M) or human RPA (3 M) was
incubated with a 5′-biotinylated 80-mer poly dT ssDNA
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(7 M) conjugated to Dynabeads M-280 Streptavidin (In-
vitrogen) for 15 min at 37◦C, in 20 l of reaction buffer,
containing 35 mM Tris-HCl (pH 8.0), 3% glycerol, 55 mM
NaCl, 1 mMAMP-PNP, 2.5 mMMgCl2, 5 mMCaCl2 and
1 mM dithiothreitol. During the incubation period, the re-
action mixtures were gently mixed by tapping at 3 min in-
tervals. The beads were then washed once with 20 l of the
reaction buffer, and were incubated with the I-D complex (4
M), which was preincubated for 15min at 37◦C, in 20l of
the reaction buffer. The reactionwas continued for 30min at
37◦C, with tapping at 3 min intervals. After the 30 min reac-
tion, the beads were washed twice with 20 l of the reaction
buffer, and the proteins bound to the beads were analyzed
by 10% SDS-PAGEwith Coomassie Brilliant Blue staining.
The band intensity of the I-D complex was quantitated with
an LAS-4000 image analyzer, using theMultiGauge ver. 3.2
software. The reactions with naked ssDNA beads were per-
formed in the absence of RAD51 and RPA.
RAD51 transfer assay
Chicken RAD51 (5.2 M) was incubated with a 5′-
biotinylated 80-mer poly dT oligo DNA (20.7 M), a 5′-
biotinylated 3′-tailed DNA (20.7 M) or a 5′-biotinylated
replication fork-like DNA (20.7 M) conjugated to Dyn-
abeads M-280 Streptavidin for 10 min at 37◦C, in 11.6 l of
reaction buffer, containing 60 mM Tris-HCl (pH 8.0), 6%
glycerol, 108 mM NaCl, 4.3 mM MgCl2, 1.7 mM adeno-
sine triphosphate (ATP) and 1.7 mM dithiothreitol. After
the incubation, the I-D complex (2.7M), which was prein-
cubated with or without the 49-mer dsDNA (20 M) for 10
min at 37◦C in 6 l of 13 mM Tris-HCl (pH 8.0) buffer,
containing 6.7% glycerol, 133 mM NaCl and 3.3 mM 2-
mercaptoethanol, was added to the reaction mixture, fol-
lowed by an incubation for 10 min at 37◦C. For the experi-
ments with the I-D complex-bound 3′-tailed DNA, the I-D
complex (94 nM) was preincubated with a 3′-tailed DNA
(10.3 M) conjugated to Dynabeads M-280 Streptavidin,
for 10 min at 37◦C, in 17 l of reaction buffer, containing
46 mM Tris-HCl (pH 8.0), 2.4% glycerol, 59 mMNaCl, 2.9
mM MgCl2, 1.2 mM ATP and 1.2 mM dithiothreitol. A
3 l aliquot of chicken RAD51 (20 M) was then added
to the reaction mixture, which was incubated for 10 min at
37◦C. The RAD51 transfer reaction was initiated by the ad-
dition of the 49-mer ssDNA oligonucleotide 1 (2.4 l, final
concentration 120 M), and was continued at 37◦C for 1 h.
During the reaction, the beadswere gentlymixed by tapping
at 3min intervals. After the reaction, the beads were washed
three times with 20 l of washing buffer, containing 35 mM
Tris-HCl (pH 8.0), 2.5 mMMgCl2, 1 mM ATP, 0.01% NP-
40 and 1 mM dithiothreitol and the proteins bound to the
beads were analyzed by 10% SDS-PAGE with Coomassie
Brilliant Blue staining. The band intensity of the I-D com-
plex was quantitated with an LAS-4000 image analyzer, us-
ing the MultiGauge ver. 3.2 software.
Gel-Filtration assay
Gel-filtration analyses were performed with 100 l of
FANCI (5 M), FANCD2 (5 M) or the I-D complex (5
M), as described previously (54,55). The peak fractions
at the 7.5-15 ml elution volume were analyzed by 8% SDS-
PAGE with Coomassie Brilliant Blue staining.
DNA binding assay
For the experiments with FANCI and FANCD2, the 49-
mer dsDNA (5 M)was incubated with FANCI, FANCD2
or the I-D complex in 10 l of reaction buffer, containing
20 mM Tris–HCl (pH 8.0), 40 mM NaCl, 2% glycerol, 5
g/ml BSA and 0.5 mM dithiothreitol, for 10 min at 37◦C.
For the experiments with the I-D-dsDNA complex, the I-D
complex (1 M) was incubated with or without the 49-mer
dsDNA (3.8 M) for 10 min at 37◦C, in 8 l of 50 mM
Tris-HCl (pH 8.0) buffer, containing 4.4% glycerol, 96 mM
NaCl, 1.3 mM ATP, 3.1 mM MgCl2 and 1.3 mM dithio-
threitol. After the incubation, a 2 l aliquot of the ssDNA
mixture (500 M oligonucleotide 1 and 15 M 32P-labeled
oligonucleotide 1) was added to the reaction mixture, which
was incubated for 5 min at 37◦C. For the experiments with
RAD51, the 49-mer ssDNA oligonucleotide 1 (5 M) or
the 49-mer dsDNA (5 M) was incubated with RAD51 in
10 l of reaction buffer, containing 28 mMHEPES-NaOH
(pH 7.5), 60 mMNaCl, 4% glycerol, 2.5 mMMgCl2, 1 mM
ATP, 5 g/ml BSA and 1 mM dithiothreitol, for 10 min at
37◦C. The samples were then analyzed by 3.5%or 6%PAGE
in 0.2x TBE (18 mM Tris-borate and 0.4 mM EDTA for
FANCI, FANCD2 and the I-D complex) or 0.5x TBE (45
mM Tris-borate and 1 mM EDTA for RAD51) buffer. The
DNA was visualized by SYBR Gold (Invitrogen) staining.
In the control experiments, the samples were deproteinized
by adding 2 l of 1.4% SDS and 8.5 g/ml proteinase K,
followed by an incubation for 5 min at 37◦C, before the elec-
trophoresis. The band intensity of the free DNA was quan-
titated with an LAS-4000 image analyzer or an FLA-7000
laser scanner (Fujifilm), using theMultiGauge ver. 3.2 soft-
ware.
Nuclease protection assay
Chicken RAD51 (0.36 M) was incubated with 32P-labeled
3′-tailed DNA (1.4 M) or 32P-labeled replication fork-like
DNA (1.4M) for 10min at 37◦C, in 7l of reaction buffer,
containing 26mMTris-HCl (pH 8.0), 4.3% glycerol, 71mM
NaCl, 1.4 mM MgCl2, 1.4 mM MnCl2, 1.4 mM ATP, 0.14
mg/ml BSA and 7.1 mM dithiothreitol. The I-D complex
(1 M), which was preincubated with the 49-mer dsDNA
(3.8 M) for 10 min at 37◦C in 2 l of 10 mMTris-HCl (pH
8.0) buffer, containing 5% glycerol, 100 mM NaCl and 2.5
mM 2-mercaptoethanol, was added, and the mixture was
incubated for 10 min at 37◦C. The nucleolytic reaction was
initiated by the addition of the FAN1 nuclease domain (1
l, final concentration 0.4 M), and was continued for 30
min at 37◦C. The reaction was stopped by the addition of
2 l of 1.4% SDS and 8.5 g/ml proteinase K, followed by
an incubation for 15 min at 37◦C. After deproteinization,
Hi-Di formamide (50l, Applied Biosystems) was added to
each sample. The samples were boiled for 10 min at 100◦C,
and were immediately cooled on ice for 5 min. The samples
were then fractionated by 12% urea denaturing PAGE in
1x TBE buffer (89 mM Tris-borate and 2 mM EDTA). The
gels were exposed to an imaging plate (Fujifilm), and the
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Figure 1. Stable RAD51 targeting to the stalled replication forks requires FANCD2. (A–C) Replication stress-induced foci formation of RAD51. (A)
1BR3.hTERT fibroblasts transfected with control or FANCD2 siRNA were treated with MMC, and the RAD51 foci were visualized by staining with
an anti-RAD51 antibody after incubations for the indicated times. (B) PD20F cells expressing GFP-FANCD2, GFP-FANCD2 K561R (KR) and GFP
alone were used for the MMC-induced RAD51 foci formation assay. (C) U2OS cells transfected with control or FANCD2 siRNA were treated with
hydroxyurea (HU), and the RAD51 foci intensities were analyzed. The normalized intensities of RAD51 foci are represented as dot plots. Red horizontal
lines denote means with standard deviations. Statistical differences were determined by the Student’s t-test; *P < 0.01, **P < 0.0001, n.s., not significant.
(D and E) In situ proximity ligation assay (PLA). (D) The PLA signals (red) between RAD51 and FLAG-tagged FANCD2 were visualized by staining
with anti-RAD51 and anti-FLAG antibodies, in the untreated cells and the cells treated with MMC or HU. (E) U2OS cells transfected with control or
FANCD2 siRNA were treated with or without HU, and the PLA signals between RAD51 and PCNA were visualized by staining with anti-RAD51 and
anti-PCNA antibodies. The numbers of PLA signals were counted and represented as dot plots. DNA was counterstained with DAPI (blue). Bar: 10 m.
Red horizontal lines denote means with standard deviations. Statistical differences were determined by the Student’s t-test; **P< 0.0001. (F) Fluorescence
recovery after photobleaching (FRAP) analysis of GFP-RAD51 foci. Two days after the transfection of the control or FANCD2 siRNA, the mobility of
GFP-RAD51 was analyzed by bleaching the RAD51 foci, with or without MMC treatment (100 ng/ml, for 24 h). The means of the relative fluorescence
intensities with standard deviations (n = 20–22) and representative images are shown. The bleached area is indicated as an open square.
DNA bands were visualized using an FLA-7000 imaging
analyzer. The band intensities were quantitated using the
Image J 1.46r software.
RESULTS AND DISCUSSION
FANCD2 is required for stable RAD51 association at repli-
cation forks stalled by ICLs
In cells, RAD51-foci intensity was remarkably increased
at 15–25 h after treatment with a DNA crosslinker, mito-
mycin C (MMC), which stalls replication fork progression
(Figure 1A, experiments with a control siRNA). We found
that the MMC-induced RAD51 foci formation was signif-
icantly suppressed at a later time point of MMC treatment
in the FANCD2-knockdown cells (Figure 1A, experiments
with a FANCD2 siRNA), in which the expression level
of FANCD2 was substantially decreased by a FANCD2-
specific siRNA to <5% of that in the cells treated with con-
trol siRNA (Supplementary Figure S1A). The exogenous
production of FANCD2 in FANCD2-deficient PD20F pa-
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Figure 2. FANCD2 and FANCI interact with RAD51. (A) Pull-down assay with the HeLa cell extracts. The beads without RAD51 (N) or with RAD51
(R) were incubated with the nuclease-treated cell extracts, and the proteins bound to the beads were detected by Western blotting. The cell extracts were
prepared from untreated and MMC-treated HeLa cells. (B) Pull-down assay with the DT40 cell extracts. The nuclease-treated cell extracts were prepared
from untreated, MMC-treated and HU-treated DT40 cells. (C) Pull-down assay with Ni-NTA beads. RAD51 bound to His6-tagged FANCI, FANCD2
and the I-D complex was copelleted with the Ni-NTA beads, and the proteins were analyzed by SDS-PAGE. (D) Pull-down assay with single-stranded
DNA (ssDNA) beads. The beads conjugated with ssDNA, the RAD51-ssDNA complex or the RPA-ssDNA complex were incubated with the I-D complex.
The I-D complex that copelleted with the beads was analyzed by SDS-PAGE. The amounts of the I-D complex in the bound fractions were quantitated,
and the mean percentages of three independent experiments are indicated with the standard deviations. (E) Pull-down assay with His6-tagged RAD51
proteins. The I-D complex was copelleted with His6-RAD51 or His6-RAD51 F86E bound to Ni-NTA beads, and the proteins were analyzed by SDS-
PAGE with Coomassie Brilliant Blue staining. The amounts of the I-D complex in the bound fractions were quantitated, and the mean percentages of
three independent experiments are indicated with the standard deviations.
tient cells complemented the MMC-induced RAD51 foci
formation (Figure 1B). The monoubiquitination-deficient
FANCD2 K561R mutant, which is defective in chromatin
targeting (8), did not complement the defective RAD51 re-
cruitment in PD20F cells (Figure 1B). In the PD20F cells,
HU, a chemical compound that induces replication fork
stalling, promotes the degradation of the stalled replication
fork (44). Consistently, in the FANCD2-knockdown cells,
the formation of RAD51 foci induced by HU was also sup-
pressed (Figure 1C and Supplementary Figure S1B).
The interaction between RAD51 and FANCD2 in cells
was then verified by an in situ PLA. In this assay, the
PLA signals are observed as fluorescent foci, if RAD51 and
FANCD2 are localized in close proximity in cells (<40 nm)
(56). As shown in Figure 1D, detectable amounts of PLA
signals were observed in the nuclei of untreated U2OS cells
expressing FLAG-tagged FANCD2, while the number of
PLA signals was very low in cells treated with either the
anti-FLAG or anti-RAD51 antibody alone (Supplemen-
tary Figure S1C). In addition, a significant increase in the
PLA signal number was observed after the MMC or HU
treatment, which stalls replication fork progression (Fig-
ure 1D). Importantly, the MMC-induced PLA signals were
barely detected with either the anti-FLAG or anti-RAD51
antibody alone, although they were robustly detected in
the presence of both anti-FLAG and anti-RAD51 antibod-
ies (Supplementary Figure S1D). We also found that the
PLA signals with RAD51 and PCNA were significantly re-
duced in the FANCD2-knockdown cells after the HU treat-
ment (Figure 1E), indicating that FANCD2 is required for
the RAD51 accumulation at the stalled replication forks.
Therefore, FANCD2 may directly bind to RAD51, proba-
bly on the stalled replication fork in cells.
To assess the stability of RAD51 at the stalled replication
forks, we performed the FRAP experiments before and after
the MMC treatment, in cells with and without FANCD2.
The FRAPmeasurements were performed for each RAD51
focus. Before the MMC treatment, the RAD51 mobility re-
mained unchanged in the FANCD2-knockdown cells (Fig-
ure 1F, left). However, the RAD51 mobility was clearly in-
creased in the FANCD2-knockdown cells after the MMC
treatment (Figure 1F, right). These results directly showed
that FANCD2 stabilizes the RAD51 bound to stalled repli-
cation forks induced by ICLs.
The I-D complex binds to RAD51
FANCD2 reportedly recruits CtIP to the stalled replica-
tion fork (47). CtIP is known to mediate the DNA end re-
section, which is prerequisite for subsequent RAD51 load-
ing. This suggested the possibility that FANCD2 may indi-
rectly recruit RAD51 through the CtIP function. To elim-
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Figure 3. The I-D complex stabilizes the RAD51-DNA nucleoprotein filament. (A) Schematic diagram of the RAD51 transfer assay with ssDNA beads.
(B and C) RAD51 transfer assay with ssDNA beads in the presence of (B) the I-D complex or the (C) I-D-dsDNA complex. The RAD51 retained on the
ssDNA beads was analyzed by SDS-PAGE and quantitated. The mean percentages of three independent experiments are indicated as bars with standard
deviations. (D) Schematic diagram of the RAD51 transfer assay with 3′-tailed DNA beads. (E) RAD51 transfer assay with 3′-tailed DNA beads in the
presence of the I-D-dsDNA complex. The RAD51 retained on the 3′-tailed DNA beads was analyzed, as in panel C. (F) Schematic diagram of the RAD51
transfer assay with the I-D complex-bound 3′-tailedDNAbeads. (G) RAD51 transfer assay with the I-D complex-bound 3′-tailedDNAbeads. TheRAD51
retained on the 3′-tailed DNA beads was analyzed, as in panel C. (H) Schematic diagram of the RAD51 transfer assay with replication fork-like DNA
beads. (I) RAD51 transfer assay with replication fork-like DNA beads in the presence of the I-D-dsDNA complex. The RAD51 retained on the replication
fork-like DNA beads was analyzed, as in panel C.
inate this possibility, we tested whether FANCD2 binds to
RAD51. To do so, we prepared RAD51-conjugated beads,
and then performed the pull-down assay with human cell
extracts. Endogenous FANCD2 copelleted with RAD51
beads, together with FANCI, indicating that the endoge-
nous I-D complex binds to RAD51 (Figure 2A). TheMMC
treatment stimulated the FANCD2 monoubiquitination
and both the ubiquitinated and non-ubiquitinated forms
of FANCI and FANCD2 efficiently bound to RAD51
(Figure 2A). This RAD51-FANCI-FANCD2 interaction
was also detected in pull-down assays with chicken DT40
cell extracts (Figure 2B). These pull-down assays were
performed with cell lysates treated with a nuclease, ben-
zonase, thus suggesting that RAD51 binds to the DNA-
free I-D complex. We then tested the direct interaction be-
tween RAD51 and the I-D complex, using purified chicken
RAD51, FANCI and FANCD2 (Supplementary Figure
S2A and B). We found that RAD51 was efficiently cap-
tured by the Ni-NTA agarose beads bound to His6-tagged
FANCI, FANCD2 or the I-D complex (Figure 2C). These
results indicated that both subunits of the I-D complex di-
rectly bind to RAD51. The I-D complex also bound to
DMC1, a meiosis-specific RAD51 isoform, but its affinity
was quite low, as compared to that of RAD51 (Supplemen-
tary Figure S2C and D).
RAD51 binds to ssDNA, and forms the RAD51-ssDNA
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Figure 4. Preparation of FANCI and FANCD2 mutants. (A) Schematic representation of the chicken FANCD2(Ex7) mutant. The basic amino acids
Lys361, Lys369, Arg399, Lys400, Lys404, Arg407 and Lys974, located near the predicted DNA-binding surface of FANCD2 (64), were replaced by
Glu. Alignment of the amino-acid sequences of the Homo sapiens, Mus musculus and Gallus gallus FANCD2 proteins, with the residues mutated in
this study colored red. (B) The purified FANCI(Ex6) and FANCD2(Ex7) mutants. FANCI(Ex6) and FANCD2(Ex7) were analyzed by 12% SDS-PAGE
with Coomassie Brilliant Blue staining. (C) DNA binding assay with FANCI(Ex6) and FANCD2(Ex7). The 49-mer dsDNAwas incubated with increasing
amounts (0, 0.2, 0.4 and 0.6M)ofFANCD2,FANCD2(Ex7), FANCI orFANCI(Ex6) and the sampleswere analyzed by PAGEwith SYBRGold staining.
Lanes 5, 10, 15 and 20 indicate control experiments, in which the samples were deproteinized before electrophoresis. (D) Graphic representation of the
experiments shown in panel C. The intensity of the free DNA band was quantitated, and the amounts of DNA bound to the proteins were estimated.
The mean percentages of three independent experiments are plotted against the protein concentration, with standard deviations. (E–G) Gel filtration
analysis of the I-D complex formation. FANCI, FANCD2 and the mixture of FANCI and FANCD2 were fractionated on the Superdex 200 gel filtration
column. The peak fractions (elution volume 7.5–15 ml) were analyzed by 8% SDS-PAGE with Coomassie Brilliant Blue staining. Experiments with (E)
FANCI and FANCD2, (F) FANCI(Ex6) and FANCD2, (G, top) FANCI and FANCD2(Ex7) and (G, bottom) FANCI(Ex6) and FANCD2(Ex7). The
void volume of the Superdex 200 column and the elution volumes of thyroglobulin (669 kDa), catalase (232 kDa) and conalbumin (75 kDa) are indicated
on the gel filtration profiles. (H) DNA binding assay with the I-D complex mutants. Experiments were performed by the same method as in panel C. The
concentrations of the I-D, I-D(Ex7), I(Ex6)-D2 and I(Ex6)-D2(Ex7) complexes were 0, 0.1, 0.2 and 0.4 M. (I) Graphic representation of the experiments
shown in panel H. The amounts of DNA bound to the proteins were analyzed, as in panel D.
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Figure 5. The DNA binding activity of FANCI is required for the I-D complex-mediated stabilization of the RAD51-DNA filament. (A) The RAD51
transfer assay with ssDNA beads in the presence of the I-D, I-D(Ex7), I(Ex6)-D or I(Ex6)-D(Ex7) complex. The RAD51 retained on the ssDNA beads
was analyzed, as in Figure 3C. (B) The purified His6-tagged FANCI(Ex6) and FANCD2(Ex7) mutants. His6-FANCD2(Ex7) and His6-FANCI(Ex6)
were analyzed by 12% SDS-PAGE with Coomassie Brilliant Blue staining. (C) Pull-down assay with His6-FANCD2(Ex7). RAD51 bound to His6-tagged
FANCD2 or His6-tagged FANCD2(Ex7) was copelleted by the Ni-NTA beads, and the proteins were analyzed by 10% SDS-PAGE with Coomassie
Brilliant Blue staining. (D) Pull-down assay with His6-FANCI(Ex6). Experiments were performed by the same method as in panel C, except with 12%
SDS-PAGE with Coomassie Brilliant Blue staining.
filament in the presence of ATP (57–60). We then tested
whether the I-D complex binds to the RAD51-ssDNA fila-
ment.We assembled the RAD51-ssDNAfilament with poly
dT ssDNA conjugated to magnetic beads (ssDNA beads)
in the presence of a non-hydrolyzable ATP analog, AMP-
PNP, which allows stable RAD51-filament formation on
ssDNA. The purified I-D complex copelleted with the ss-
DNA beads, because the I-D complex itself binds to ss-
DNA (17) (Figure 2D, lane 2). Interestingly, however, a sub-
stantial amount of the I-D complex was captured with the
RAD51-ssDNA filament, as compared to the experiments
without RAD51 (Figure 2D, lane 4). In contrast, the I-D
complex did not copellet with RPA-coated ssDNA, which
is formed at stalled forks before RAD51 loading (36) (Fig-
ure 2D, lane 6, and Supplementary Figure S2E). These re-
sults indicated that the I-D complex specifically binds to the
RAD51-ssDNA complex, but not the RPA-ssDNA com-
plex, probably by its RAD51-binding activity.
Intriguingly, we found that the I-D complex bound more
efficiently to the RAD51 F86E mutant, which is reportedly
defective in the polymer formation (61), than the wild-type
RAD51 (Figure 2E and Supplementary Figure S2F). In
the RAD51 F86E mutant, the RAD51–RAD51 interface,
which is buried by the polymer formation, is exposed to the
solvent. This finding suggested that the I-D complex may
bind to the buried RAD51 surface in the RAD51 polymer.
Such RAD51 surface may be accessible at the end of the
RAD51 polymer. Therefore, the I-D complex may bind to
the end of the RAD51 filament, formed on the stalled repli-
cation fork (See Figure 7).
The I-D complex bound to DNA stabilizes the RAD51–DNA
filament
To evaluate the effect of the I-D complex binding to the
RAD51-DNA complex, we performed the RAD51 transfer
assay (Figure 3A). In this assay, the RAD51–ssDNA fila-
ment was assembled on the ssDNA beads in the presence
of ATP. A competitor ssDNA (10-fold molar excess) was
then added, which stripped the RAD51 from the RAD51–
ssDNA beads. The residual RAD51 on the ssDNA beads
was finally estimated by SDS-PAGE (Figure 3B). Under the
conditions used here, about 60% of the RAD51 was disas-
sembled from the RAD51–ssDNA beads in the presence
of the competitor DNA (Figure 3B, lanes 2 and 3). The
RAD51 transfer was not detected in the presence of AMP–
PNP that stabilizes the RAD51 filament on the ssDNA
(Supplementary Figures S3A and B). The I-D complex
slightly increased the amount of RAD51 retained on the ss-
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Figure 6. The I-D complex protects a DNA end from undesired nucleolytic processing by RAD51-DNA filament stabilization. (A) Schematic diagram of
the nuclease protection assay with the 3′-tailed DNA. (B) The 3′-tailed DNA, labeled at the 5′-end of the short strand with 32P, was incubated with the
FAN1 nuclease domain or the FAN1D977Amutant, and the resulting DNA fragments were analyzed by denaturing PAGE. (C) Nuclease protection assay
with the 3′-tailed DNA. RAD51 or RAD51 T131P (TP), which contained a mutation found in a FANCR patient, was assembled on the 3′-tailed DNA in
the presence of the I-D, I-D(Ex7), I(Ex6)-D or I(Ex6)-D(Ex7) complex that was preincubated with dsDNA. After an incubation with FAN1, the resulting
DNA fragments were analyzed by denaturing PAGE. Band intensities of undigested 32P-labeled strand DNA were quantitated, and mean percentages of
three independent experiments are indicated as bars with standard deviations. (D) Schematic diagram of the nuclease protection assay with the replication
fork-like DNA. (E) The replication fork-like DNA, with the 5′-end of the shortest strand labeled with 32P, was incubated with the FAN1 nuclease domain
or the FAN1 D977A mutant, and the resulting DNA fragments were analyzed, as in panel B. (F) Nuclease protection assay with the replication fork-like
DNA. Experiments were performed as in panel C. Stars denote 32P at a 5′-DNA end.
DNA beads (Figure 3B, lane 4). In this assay, the I-D com-
plex bound to the RAD51-ssDNA filament was co-pelleted
(Figure 3B, lane 4). This indicates that the I-D complex
alone does not affect the stability of the RAD51–ssDNA
complex. However, unexpectedly, the I-D complex bound
to a 49-mer double-stranded DNA (I-D-dsDNA complex)
significantly stabilized the RAD51–ssDNA complex (Fig-
ure 3C, lane 5), although the dsDNAalone used for the I-D-
dsDNA complex stripped the RAD51 bound to the ssDNA
beads (Figure 3C, lane 3). The I-D-dsDNA complex did not
bind to the free ssDNA (Supplementary Figure S3C), elim-
inating the possibility that the I-D-dsDNA complex bound
and sequestered the competitor ssDNA. Since the RAD51
filament is assembled on the ssDNA–dsDNA junction by
BRCA2 (62), we hypothesized that the I-D complex may
stabilize the RAD51 nucleoprotein filament formed on the
ssDNA–dsDNA junction (Figure 3D). Consistent with this
idea, the I-D-dsDNA complex robustly enhanced the sta-
bility of the RAD51 filament formed on the 3′-tailed DNA
(Figure 3E). These results indicated that the I-D complex
bound to dsDNA stabilizes the RAD51-DNA complex.
We then tested whether the I-D complex pre-bound to
the 3′-tailed DNA stabilizes the RAD51–ssDNA filament
in cis. In this experiment, the I-D-3′-tailed DNA complex
was formed in an I-D: 3′-tailedDNA= 1.4: 1molar ratio (in
molecules). We found that the I-D complex pre-assembled
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Figure 7. Model for cooperative function of the ID complex and RAD51
in replication fork protection. The I-D complex preferentially binds to the
branched DNA structure at the stalled replication fork. RAD51 is sub-
sequently assembled on the ssDNA region, and forms the nucleoprotein
filament covering the ssDNA-dsDNA junction. The I-D complex, which
directly binds to RAD51, prevents RAD51 from dissociating from the end
of the nucleoprotein filament. Consequently, the RAD51 nucleoprotein fil-
ament is stabilized, and the ssDNA-dsDNA junction may not be accessi-
ble to exonucleases. In the I-D complex-deficient cells, the spontaneous
disassembly of RAD51 may allow an exonuclease to access the 5′-end of
the newly synthesized lagging strand and induce undesired replication fork
degradation, leading to chromosomal aberrations.
on the 3′-tailed DNA also stabilizes the RAD51–DNA fil-
ament (Figure 3F and G). This may explain how the I-D
complex protects stalled replication forks fromdegradation,
via the RAD51-filament stabilization (44).
Finally, we performed the RAD51 transfer assay with the
replication fork-like DNA. As shown in Figure 3H and I,
the I-D-dsDNA complex efficiently stabilized the RAD51
complex formed on the replication fork-like DNA.
The DNA binding activity of FANCI, but not FANCD2, in
the I-D complex is required for the RAD51-DNA filament
stabilization
We next determined whether the DNA-binding activity of
the I-D complex is essential for the RAD51–ssDNA stabi-
lization. To do so, we purified the FANCI and FANCD2
mutants, FANCI(Ex6) and FANCD2(Ex7), which are de-
fective in the DNA-binding activity (Figure 4B). TheDNA-
binding deficient FANCI(Ex6) mutant was established pre-
viously (18). We then designed the FANCD2(Ex7) mu-
tant (Figure 4A). As shown in Figure 4C and D, both
FANCI(Ex6) and FANCD2(Ex7) were completely de-
fective in DNA binding. In contrast, FANCI(Ex6) and
FANCD2(Ex7) retained the normal I-D complex formation
activity (Figure 4E–G).
We then tested the DNA binding activities of the I-
D complexes, I(Ex6)-D, I-D(Ex7) and I(Ex6)-D(Ex7). We
found that I(Ex6)-D and I-D(Ex7) still retained the DNA
binding activity, although it was less than half of that of the
ID complex (Figure 4H and I). As expected, I(Ex6)-D(Ex7)
was completely defective in the DNA binding activity (Fig-
ure 4H and I).
Intriguingly, we found that the I(Ex6)-D complex in-
cubated with dsDNA was significantly defective in the
RAD51–ssDNA complex stabilization (Figure 5A, lane 7).
Similarly, the I(Ex6)-D(Ex7) complex incubated with ds-
DNA was also defective in this activity (Figure 5A, lane 8).
In sharp contrast, the I-D(Ex7) complex incubated with ds-
DNA was completely proficient in the stabilization of the
RAD51–ssDNA complex (Figure 5A, lane 6). These re-
sults indicated that the DNA-binding of FANCI, but not
FANCD2, is responsible for the I-D complex-mediated sta-
bilization of the RAD51–ssDNA complex. In this assay,
the RAD51–ssDNA beads reproducibly captured smaller
amounts of the I-D complexes containing the FANCI(Ex6)
mutant (Figure 5A, lanes 7 and 8), although equal amounts
of the input I-D complexes were used.Neither FANCI(Ex6)
nor FANCD2(Ex7) exhibited any obvious defect in the
RAD51-binding activity (Figure 5B–D). The low amount
of the I(Ex6)-D complex detected in this assay may be re-
sponsible for the low amount of RAD51 retained on the
ssDNA beads.
The RAD51–DNA filament stabilized by the I-D complex
protects the DNA end
The I-D complex and RAD51 reportedly play essential
roles for preventing improper nascent DNA resection at a
stalled replication fork (44). The 5′-3′ exonucleases, such as
FAN1 and DNA2, have been implicated in such destruc-
tiveDNAdegradation (33,40,41).We then assessedwhether
the RAD51-filament stabilization by the I-D-dsDNA com-
plex functions to protect the 5′-DNA end at the ssDNA–
dsDNA junction. To do so, we performed the nuclease pro-
tection assay (Figure 6A). In this assay, the RAD51 nucleo-
protein filament was assembled on a 3′-tailed DNA, which
contained an ssDNA–dsDNA junction, with ATP and then
incubated with the FAN1 nuclease domain (Supplementary
Figure S4A). The 5′-end of the shorter strand, located at the
ssDNA–dsDNA junction, was labeled by 32P. Consistent
with a previous report (63), the labeled 5′-end at the DNA
junction was completely nibbled by FAN1, but not by the
nuclease-deficient FAN1 D977A mutant (Figure 6B, lanes
2 and 3). The FAN1-mediated DNA nibbling was weakly
protected in the presence of RAD51 (Figure 6C, lanes 2 and
3). However, the 5′-DNA end protection by RAD51 was re-
markably stimulated by the I-D-dsDNA complex (Figure
6C, lane 5), although the I-D-dsDNA complex alone did
not inhibit the FAN1 nuclease activity (Figure 6C, lane 4).
The DNA-binding activity of FANCI in the I-D complex
was strictly required for the DNA protection by RAD51, as
revealed by the I-D complexes containing theDNA-binding
deficient FANCI(Ex6), but not FANCD2(Ex7) (Figure 6C,
lanes 7, 9 and 11). FANCR-patient cells containing the
RAD51 T131Pmutation reportedly exhibit excessive nucle-
olytic degradation of the stalled replication fork, leading
to chromosomal aberrations (33). Consistently, we found
that the RAD51 T131P mutant was defective in protect-
ing the 5′-DNA end of the tailed DNA from FAN1, even
in the presence of the I-D-dsDNA complex (Figure 6C,
lanes 12 and 13, and Supplementary Figure S4B–D). We
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repeated the nuclease protection assay using a replication
fork-like DNA substrate, and confirmed that the results are
perfectly consistent with those from the experiments with
the 3′-overhang DNA (Figure 6D–F).
Collectively, the I-D complex-mediated stabilization of
the RAD51 nucleoprotein filament may function to pre-
vent destructive DNA degradation by exonucleases during
replication and at stalled replication forks. Since the I-D
complex preferentially binds to branched DNA (17), it may
prevent RAD51 dissociation from the end of the RAD51–
DNA filament at the stalled replication fork (Figure 7). In
addition, the binding of the I-D complex to the end of the
RAD51 filament was also suggested by the enhanced I-D
complex binding to the RAD51 F86E mutant, which is de-
fective in the RAD51 polymer formation (Figure 2E). The
stable RAD51–DNAfilament covering the ssDNA-dsDNA
junctionmay substantially protect its 5′-end from undesired
nucleolytic degradation by exonucleases.
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